SCHEMBL1751341

SCHEMBL1751341

[C]1c2ccccc2CCc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
CES1 P23141 1/20 0.40
ORAI1 Q96D31 1/20 0.39
ORAI2 Q96SN7 1/20 0.39
ORAI3 Q9BRQ5 1/20 0.39
CYP2A6 P11509 1/20 0.39
HTR2C P28335 1/20 0.38
RET P07949 1/20 0.34
HTR2A P28223 1/20 0.34
NPC1 O15118 1/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
MAOB P27338 4/20 0.33
CYP1A2 P05177 1/20 0.33
PNMT P11086 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11095966 1.00 TSHR (0.43) TSHRCES1ORAI1ORAI2ORAI3
SCHEMBL8912020 1.00 TSHR (0.43) TSHRCES1ORAI1ORAI2ORAI3
SCHEMBL925838 0.83 CES1 (0.43) TSHRCES1ORAI1ORAI2ORAI3
SCHEMBL327799 0.82 TSHR (0.43) TSHRCES1ORAI1ORAI2ORAI3
SCHEMBL1750072 0.82 MAOA (0.42) TSHRCES1CYP2A6HTR2CHTR2A
SCHEMBL31251596 0.82 TSHR (0.43) TSHRCES1ORAI1ORAI2ORAI3
SCHEMBL1750074 0.82 MAOA (0.42) TSHRCES1CYP2A6HTR2CHTR2A
SCHEMBL4234812 0.79 GRIN1 (0.33) HTR2CHTR2AMAPK14DRD2DRD3
SCHEMBL2537276 0.76 HRH1 (0.36) TSHRHTR2CHTR2ADRD2
SCHEMBL7473156 0.76 DRD2 (0.35) TSHRHTR2CHTR2APNMTDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2096104-A1 Organic diamines as mGluR7 modulators Novartis AG (CH) 2009-09-02 EP claimed
US-20080242698-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-02 US claimed
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 US claimed
EP-1924551-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-05-28 EP claimed
US-7348351-B2 Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2008-03-25 US claimed
WO-2007025709-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-03-08 WO claimed
EP-1569899-B1 SUBSTITUTED 3-ALKYL- AND 3-ARYLALKYL-1H-INDOL-1-YL-ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH CORP (US) 2006-06-28 EP claimed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 US claimed
US-20040116488-A1 Substituted 3-alkyl and 3-arylalkyl 1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2004-06-17 US claimed
US-6306853-B1 DICARBOXYLIC ESTER DERIVATIVES OF DIHYDROPYRIDINE COMPOUNDS NIKKEN CHEMICALS CO., LTD. (JP) 2001-10-23 US claimed
US-5030646-A Treatment of diseases resulting from disfunction of seretoninergic system ADIR ET COMPAGNIE (FR) 1991-07-09 US claimed
US-5024912-A 5H-dibenzo(A,D) cycloheptanylidene derivative and 5H-dibenzo (A,D) cycloheptenylidene derivative, and electrophotographic photosensitive member using the same CANON KABUSHIKI KAISHA (JP) 1991-06-18 US claimed
US-4877779-A CALCIUM CHANNEL BLOCKERS; TREATMENT OF IRRITABLE BOWEL SYNDROME MARION LABORATORIES, INC. (US) 1989-10-31 US claimed
EP-0109299-A2 1,1-Disubstituted-2-heterocyclic ethanol derivatives ELI LILLY AND COMPANY (US) 1984-05-23 EP claimed
US-4382934-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-05-10 US claimed
EP-0010398-B1 ISATIN DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-04-27 EP claimed
EP-0005318-B1 N-HETEROCYCLYL-4-PIPERIDINAMINES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, INTERMEDIATES THEREFOR, AND METHOD FOR THE PREPARATION OF THE INTERMEDIATES JANSSEN PHARMACEUTICA N.V. (BE) 1982-01-06 EP claimed
EP-0010398-A1 Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-04-30 EP claimed
US-4116665-A Method of regulating the growth of aquatic weeds with pyridine derivatives ELI LILLY AND COMPANY (US) 1978-09-26 US claimed
US-4002624-A HERBICIDES, FUNGICIDES, INSECTICIDES, ANTIMICROBIALS THE DOW CHEMICAL COMPANY (US) 1977-01-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242698-A1 Organic Compounds AOC1, OTC, ODC1 TSHR 4417/4885CES1 4282/4885ORAI1 377/4885
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS BACE1, PSEN1, BACE2 TSHR 412/4885CES1 791/4885ORAI1 20/4885
US-20050119329-A1 Tetronic and tetramic acids BACE1, PSEN1, BACE2 TSHR 412/4885CES1 791/4885ORAI1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.